Drug Profile
Tafamidis meglumine - Pfizer
Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Tafamidis free acid; VYNDAMAX; Vyndaqel; VynmacLatest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator FoldRx Pharmaceuticals
- Developer Pfizer
- Class Benzoxazoles; Carboxylic acids; Cardiovascular therapies; Chlorobenzenes; Neuroprotectants; Small molecules
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Amyloid polyneuropathy; Cardiomyopathies
Most Recent Events
- 23 Feb 2024 Pfizer plans a phase I pharmacokinetics trial (In volunteers) (PO) in February 2024 (NCT06273839)
- 23 Nov 2023 Pfizer completes a phase III extension trial for Cardiomyopathy in USA, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Hong Kong, Taiwan, Italy, Japan, Netherlands, Spain, Sweden, the United Kingdom (PO) (NCT02791230)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Cardiomyopathies(In volunteers) in USA (PO, Tablet)